A report from the U.S. FDA's Office of Inspector General is calling ... and Biogen (NASDAQ:BIIB) as examples. The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback